Bio-Rad Laboratories buys GnuBIO

GnuBIO, a privately-held life sciences company that has developed a droplet-based DNA sequencing technology, today announced that it was acquired by Bio-Rad Laboratories, Inc. With this acquisition, Bio-Rad will expand its Digital Biology Center and establish a research and development site in Cambridge, Massachusetts.

GnuBIO, www.gnubio.com, has developed a DNA sequencing solution that integrates the entire sample preparation workflow on a chip, from sample capture, PCR, and sequencing, to informatics. This capability offers a "Sample In, Answer Out" DNA sequencing solution whereby a technician or researcher simply loads genomic DNA into the cartridge and presses a button to start the run with results delivered within hours, versus days.

"Bio-Rad's leading positions in the clinical IVD market as well as the Droplet Digital™ PCR space make Bio-Rad the ideal acquisition partner for us," said John Boyce, President, CEO, and Founder of GnuBIO. "Bio-Rad's reputation as well as its presence in both the clinical and research markets will be essential elements to the success of the GnuBIO platform. We are very excited to join the Bio-Rad family," Boyce added.